It is widely recognized that the welfare of the most advanced economies is at risk, and that the only way to tackle this
situation is by controlling the knowledge economies and dealing with. To achieve this ambitious goal, we need to
improve the performance of each dimension in the "knowledge triangle": education, research and innovation. Indeed,
recent findings point to the importance of strategies of adding-value and marketing during R+D processes so as to bridge
the gap between the laboratory and the market and so ensure the successful commercialization of new technology-based
products. Moreover, in a global economy in which conventional manufacturing is dominated by developing economies,
the future of industry in the most advanced economies must rely on its ability to innovate in those high-tech activities
that can offer a differential added-value, rather than on improving existing technologies and products. It seems quite
clear, therefore, that the combination of health (medicine) and nanotechnology in a new biomedical device is very
capable of meeting these requisites.
This work propose a generic CMOS Front-End Self-Powered In-Vivo Implantable Biomedical Device, based on a threeelectrode
amperometric biosensor approach, capable of detecting threshold values for targeted concentrations of
pathogens, ions, oxygen concentration, etc.
Given the speed with which diabetes can spread, as diabetes is the fastest growing disease in the world, the nano-enabled
implantable device for in-vivo biomedical analysis needs to be introduced into the global diabetes care devices market.
In the case of glucose monitoring, the detection of a threshold decrease in the glucose level it is mandatory to avoid critic
situations like the hypoglycemia. Although the case study reported in this paper is complex because it involves multiple
organizations and sources of data, it contributes to extend experience to the best practices and models on nanotechnology
applications and commercialization.